Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/23866Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Filippatos, T. D. | en |
| dc.contributor.author | Tsimihodimos, V. | en |
| dc.contributor.author | Kostapanos, M. | en |
| dc.contributor.author | Kostara, C. | en |
| dc.contributor.author | Bairaktari, E. T. | en |
| dc.contributor.author | Kiortsis, D. N. | en |
| dc.contributor.author | Elisaf, M. S. | en |
| dc.date.accessioned | 2015-11-24T19:36:23Z | - |
| dc.date.available | 2015-11-24T19:36:23Z | - |
| dc.identifier.issn | 1933-2874 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/23866 | - |
| dc.rights | Default Licence | - |
| dc.title | Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1016/j.jacl.2008.06.001 | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/21291744 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S1933287408002626/1-s2.0-S1933287408002626-main.pdf?_tid=77c4a7db047aa0da621abb59534d1ec0&acdnat=1332831604_40ce41e7e0d9a12278bd3d094275896e | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2008 | - |
| heal.abstract | BACKGROUND: Orlistat significantly reduced serum triglycerides (TG) in most clinical trials. Orlistat-induced TG reduction has not been studied to determine the factors contributing to TG alterations in clinical settings. OBJECTIVE: We examined the factors influencing TG reduction during orlistat administration, alone or in combination with fenofibrate, and we investigated the effects of these treatments on apolipoprotein C-II (ApoC-II) and C-III (ApoC-III) levels. METHODS: Patients with the metabolic syndrome were randomly allocated to receive orlistat 120 mg three times daily (n = 28, O group), micronized fenofibrate 200 mg/day (n = 28, F group), or both (n = 27, OF group) for 6 months. Plasma ApoC-II and ApoC-III were determined by an immunoturbidimetric assay. RESULTS: In the O group, we observed reductions of plasma ApoC-III (P < 0.05) and ApoC-II (P = NS) levels. Fenofibrate administration significantly reduced concentrations of ApoC-II and ApoC-III, whereas the combination of orlistat and fenofibrate had an additive effect on these apolipoproteins. There were significant in-group reductions in serum TG levels in all treatment groups. Multivariate analysis showed that in O group's baseline TG levels were independently positively correlated, whereas the baseline ApoC-II levels were negatively correlated with TG-lowering. In the F group, baseline TG levels and ApoC-III reduction were significantly and independently correlated with TG reduction. OF group's baseline TG levels and ApoC-III reduction were independently positively correlated and baseline ApoC-II levels were negatively correlated with TG-lowering. CONCLUSIONS: Orlistat-mediated TG-lowering is independently associated with baseline TG and ApoC-II levels. When orlistat is combined with fenofibrate, ApoC-III reduction is another independent contributor to TG alterations. | en |
| heal.journalName | Journal of Clinical Lipidology | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Filippatos-2008-Analysis of 6-month.pdf | 101.94 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
